MBRX Files 8-K to Furnish Sept 2025 Investor Presentation

Rhea-AI Filing Summary

Moleculin Biotech, Inc. filed a Current Report on Form 8-K disclosing that on September 8, 2025 the company posted and is using an Investor Presentation dated September 2025 as its corporate presentation and furnished that presentation as Exhibit 99.1. The filing states the furnished presentation is not being "filed" under the Exchange Act and will not be incorporated by reference into future filings unless expressly identified. The report identifies the registrant, principal executive office address in Houston, Texas, trading symbol MBRX on NASDAQ, and includes the Exhibit list and Inline XBRL cover page reference.

Insights

Securities Analyst

TL;DR: Routine Regulation FD disclosure; an investor deck was furnished, not filed, which is a standard corporate communications step.

The company furnished an investor presentation as Exhibit 99.1 under Item 7.01, indicating it is distributing updated corporate materials on September 8, 2025. This disclosure follows Regulation FD practice by making the presentation publicly available and clarifies it is being furnished rather than filed, limiting automatic incorporation into SEC filings. For investors, this is a transparency/communications action rather than a financial event; no earnings, material transactions, or financial statements are included in this 8-K.

Corporate Governance Expert

TL;DR: Filing is procedural and compliant; furnishing an investor presentation is standard and signals outreach but has no standalone material financial impact.

The Form 8-K properly discloses the furnishing of corporate presentation materials and includes the required exhibit reference (99.1). The statement that the exhibit is furnished and not filed aligns with common disclosure practice to avoid automatic incorporation by reference. This is a governance-level communications event rather than a material corporate action, and the filing contains the expected cover and exhibit references without additional substantive corporate changes.

false 0001659617 0001659617 2025-09-08 2025-09-08

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): September 8, 2025

MOLECULIN BIOTECH, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware	001-37758	47-4671997
(State or Other Jurisdiction of Incorporation or Organization)	(Commission File No.)	(I.R.S. Employer Identification No.)

5300 Memorial Drive, Suite 950, Houston, TX 77007

(Address of principal executive offices and zip code)

(713) 300-5160

(Registrant’s telephone number, including area code)

(Former name or former address, if changed from last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).          Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol (s)	Name of each exchange on which registered
Common Stock, par value $.001 per share	MBRX	The NASDAQ Stock Market LLC

Item 7.01 Regulation FD Disclosure

On September 8, 2025, Moleculin Biotech, Inc. (the “Company”) is using the attached presentation for its corporate presentation posted on the Company’s website and is set forth as Exhibit 99.1 herein.

The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be “filed” for the purpose of the Securities Exchange Act of 1934, as amended (“Exchange Act”), nor shall it be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended (“Securities Act”), unless specifically identified therein as being incorporated by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. Description

99.1 InvestorPresentation dated September 2025

104 Cover page Interactive Data File (formatted as Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MOLECULIN BIOTECH, INC.
	Date:	September 8, 2025
	By:	/s/ Jonathan P. Foster
		Jonathan P. Foster